Drug Approval | February 18, 2026
FDA accepts Deciphera’s NDA for tirabrutinib in rare aggressive brain lymphoma
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
